Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

SCYX

Scynexis Inc

Apr 19 • 11:36AM ET

1.40

Dollar change -0.00
Percentage change -0.06	%

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF BSVO IWC AVSC DFAC

Index	-	P/E	1.22	EPS (ttm)	1.15	Insider Own	5.25%	Shs Outstand	37.21M	Perf Week	-2.82%
Market Cap	53.01M	Forward P/E	29.25	EPS next Y	0.05	Insider Trans	0.00%	Shs Float	35.77M	Perf Month	-0.41%
Income	67.04M	PEG	-	EPS next Q	-0.18	Inst Own	42.47%	Short Float	2.73%	Perf Quarter	-23.27%
Sales	140.14M	P/S	0.38	EPS this Y	-117.41%	Inst Trans	-0.19%	Short Ratio	4.92	Perf Half Y	-33.13%
Book/sh	1.96	P/B	0.72	EPS next Y	119.83%	ROA	62.01%	Short Interest	0.98M	Perf Year	-55.98%
Cash/sh	1.98	P/C	0.71	EPS next 5Y	-	ROE	175.97%	52W Range	1.35 - 3.87	Perf YTD	-37.03%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	76.44%	52W High	-63.72%	Beta	1.55
Dividend TTM	-	Quick Ratio	6.26	Sales past 5Y	487.70%	Gross Margin	88.36%	52W Low	4.01%	ATR (14)	0.11
Dividend Ex-Date	-	Current Ratio	6.26	EPS Y/Y TTM	183.19%	Oper. Margin	51.85%	RSI (14)	39.89	Volatility	7.89% 7.66%
Employees	29	Debt/Eq	0.21	Sales Y/Y TTM	2652.74%	Profit Margin	47.84%	Recom	1.00	Target Price	6.88
Option/Short	Yes / Yes	LT Debt/Eq	0.20	EPS Q/Q	-27.97%	Payout	0.00%	Rel Volume	0.38	Prev Close	1.40
Sales Surprise	-24.19%	EPS Surprise	-456.52%	Sales Q/Q	280.38%	Earnings	Mar 28 AMC	Avg Volume	198.53K	Price	1.40
SMA20	-7.08%	SMA50	-12.72%	SMA200	-34.67%	Trades		Volume	28,003	Change	-0.06%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-22-21	Initiated	Guggenheim	Buy	$25
Jan-06-21	Initiated	Cantor Fitzgerald	Overweight	$30
Jul-11-18	Upgrade	Needham	Hold → Buy	$5
Jun-27-18	Initiated	Maxim Group	Buy	$6
Oct-24-17	Initiated	Guggenheim	Buy	$6
Jul-10-17	Initiated	ROTH Capital	Buy	$8.50
May-09-17	Downgrade	Needham	Buy → Hold
Mar-03-17	Reiterated	RBC Capital Mkts	Outperform	$15 → $11
Oct-20-16	Initiated	H.C. Wainwright	Buy	$14
Oct-07-16	Upgrade	WBB Securities	Buy → Strong Buy	$8
Oct-03-16	Resumed	Brean Capital	Buy
Aug-17-16	Initiated	Guggenheim	Buy	$15
Aug-09-16	Upgrade	WBB Securities	Speculative Buy → Buy	$8
Aug-09-16	Reiterated	Needham	Buy	$16 → $10
Mar-28-16	Initiated	Brean Capital	Buy	$16
Dec-29-15	Initiated	WBB Securities	Strong Buy	$8
Dec-29-15	Initiated	WBB Securities	Speculative Buy	$8
Nov-16-15	Reiterated	RBC Capital Mkts	Outperform	$18 → $17
Jun-10-15	Initiated	Needham	Buy	$16
May-29-14	Initiated	RBC Capital Mkts	Outperform	$17

Show Previous Ratings

Apr-16-24 11:52AM	14 Cheap Penny Stocks to Buy According to Analysts (Insider Monkey)
Apr-09-24 04:05PM	SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) (GlobeNewswire)
Mar-28-24 11:53PM	SCYX Stock Earnings: SCYNEXIS Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace)
04:01PM	SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jan-30-24 04:05PM	SCYNEXIS to Participate in Guggenheim's 6th Annual Biotechnology Conference (GlobeNewswire)
05:15PM	Loading…
Jan-29-24 05:15PM	SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference (GlobeNewswire)
Jan-05-24 08:30AM	SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 27, in Milan, Italy (GlobeNewswire)
Dec-27-23 09:30AM	SCYNEXIS SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options (GlobeNewswire)
Nov-27-23 10:33AM	11 Cheapest Stocks With Biggest Upside (Insider Monkey)
Nov-15-23 01:15PM	SCYX STOCKHOLDERS: Contact Robbins LLP for Information About Your Rights Against Scynexis, Inc. (Business Wire)
Nov-13-23 05:55PM	Scynexis: Q3 Earnings Snapshot (Associated Press Finance)
05:17PM	SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-24-23 08:00AM	SCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM) (GlobeNewswire)
Oct-18-23 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Orthofix, and Scynexis and Encourages Investors to Contact the Firm (GlobeNewswire)
Oct-16-23 08:00AM	SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM) October 20-23 in Athens, Greece (GlobeNewswire) +6.12%
09:00PM	Loading…
Oct-02-23 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Orthofix, and Scynexis and Encourages Investors to Contact the Firm (GlobeNewswire)
Sep-27-23 08:31PM	SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME® (ibrexafungerp tablets) due to potential for cross contamination with a non-antibacterial ß-lactam drug substance (GlobeNewswire) +9.33%
07:49AM	Verve Therapeutics (VERV) Soars 13.8%: Is Further Upside Left in the Stock? (Zacks)
Sep-25-23 08:55AM	UPDATE 4-Scynexis to recall GSK-partnered antifungal on cross contamination risk (Reuters) -34.14%
Sep-20-23 04:00AM	PTC Therapeutics (PTCT) Surges 5.8%: Is This an Indication of Further Gains? (Zacks) +5.01%
Sep-04-23 01:31PM	SCYNEXIS (SCYX) Skyrockets 134% Year to Date: Here's Why (Zacks)
Aug-28-23 10:17PM	Want to Get Rich? 3 Game-Changing Penny Stocks to Buy Right Now (InvestorPlace) +11.96%
08:00AM	SCYNEXIS to Participate in September Investor Conferences (GlobeNewswire)
Aug-14-23 04:59PM	Scynexis: Q2 Earnings Snapshot (AP Finance) -6.35%
04:30PM	SCYNEXIS Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-11-23 09:09AM	10 Best Fast Growing Penny Stocks to Buy Now (Insider Monkey)
Jul-20-23 09:58AM	SCYNEXIS and Hansoh Pharma Announce NMPA Acceptance of the New Drug Application for Ibrexafungerp in China (GlobeNewswire) +5.69%
Jun-26-23 02:20PM	Deadly Fungi Are Becoming More Common and Were Running Out of Ways to Treat Them (The Wall Street Journal)
07:00AM	Doctors Desperately Need Drugs to Kill Deadly Fungi. Its an Uphill Fight. (The Wall Street Journal)
Jun-21-23 07:00AM	SCYNEXIS Announces Achievement of First Development Milestone of $25 Million Under Exclusive License Agreement with GSK (GlobeNewswire)
04:10PM	Loading…
Jun-15-23 04:10PM	SCYNEXIS to Participate in the Maxim Group Virtual Healthcare Conference (GlobeNewswire)
May-19-23 09:22AM	WBB Research Institute Webcast Highlighted the Need For a Global Response to Candida auris and Other Deadly Antimicrobial Resistant Pathogens (Newsfile)
May-12-23 08:00AM	SCYNEXIS Reports Closing of Exclusive License Agreement with GSK for BREXAFEMME® (Ibrexafungerp Tablets) (GlobeNewswire)
May-11-23 08:45AM	Scynexis (SCYX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:37AM	Scynexis: Q1 Earnings Snapshot (AP Finance)
07:00AM	SCYNEXIS Announces First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-08-23 03:38PM	SCYNEXIS, Inc.'s (NASDAQ:SCYX) largest shareholders are individual investors with 51% ownership, institutions own 48% (Simply Wall St.)
Apr-13-23 08:30AM	SCYNEXIS to Present Ibrexafungerp Data at the 33rd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) April 15-18 in Denmark (GlobeNewswire)
Apr-11-23 01:33PM	We Might See A Profit From SCYNEXIS, Inc. (NASDAQ:SCYX) Soon (Simply Wall St.)
Mar-31-23 12:31PM	Scynexis (SCYX) Inks Antifungal Drug Deal With GSK (Zacks)
08:30AM	SCYNEXIS Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-30-23 01:12PM	GSK Bets On Scynexis' FDA-Approved Antifungal Drug For Over $500M In Bio Bucks (Benzinga) +76.05%
09:36AM	Anti-Fungal Maker Scynexis Stock Soars on GSK Deal (Barrons.com)
07:05AM	GSK and SCYNEXIS Announce an Exclusive Agreement to Commercialise and Further Develop Brexafemme (ibrexafungerp), a Novel, First-in-Class Medicine to Treat Fungal Infection (GlobeNewswire)
Mar-22-23 09:25AM	CDC Rings Alarm About Deadly Fungus. 6 Things to Know. (Barrons.com) +28.21%
07:06AM	SCYNEXIS, Inc. (NASDAQ:SCYX) insiders are still down US$113k after purchasing last year, recent gain helped regain some losses (Simply Wall St.)
Mar-01-23 04:03PM	Analyst Sees Multiple Chances With Over 300% Upside Potential For This Fungal Infections Stock (Benzinga) +16.11%
Jan-14-23 07:43AM	SCYNEXIS (NASDAQ:SCYX) shareholders are up 14% this past week, but still in the red over the last five years (Simply Wall St.)
Dec-01-22 08:00AM	SCYNEXIS Announces FDA Approval of Second Indication for BREXAFEMME® (ibrexafungerp tablets) for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis (GlobeNewswire) -10.17%
Nov-30-22 08:30AM	SCYNEXIS Announces $3 Million National Institutes of Health Grant Has Been Awarded to Case Western Reserve University Researchers to Study Second Generation Fungerp (SCY-247) to Fight Drug-Resistant Fungi (GlobeNewswire)
Nov-17-22 08:30AM	SCYNEXIS Applauds the Biomedical Advanced Research and Development Authority (BARDA) for Its New Priority Focus on Investment in Development of Antifungal Treatments to Fight Infections Caused by Drug-Resistant Fungal Threats (GlobeNewswire)
Nov-11-22 05:37AM	SCYNEXIS Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.)
Nov-09-22 08:15AM	Scynexis (SCYX) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -19.64%
07:00AM	SCYNEXIS Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-07-22 08:30AM	SCYNEXIS Announces Publication of Review Article Highlighting Ibrexafungerp as a Potential Novel Treatment for Invasive Mold Infections in the Journal of Fungi (GlobeNewswire)
Nov-03-22 08:30AM	Pooled Data from the Pivotal Phase 3 VANISH Program Published in the Journal of Womens Health Demonstrate Significant Efficacy of Ibrexafungerp Over Placebo for Treatment of Vaginal Yeast Infection (GlobeNewswire)
Nov-02-22 10:01AM	Earnings Preview: Scynexis (SCYX) Q3 Earnings Expected to Decline (Zacks)
Nov-01-22 08:30AM	SCYNEXIS to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 9 (GlobeNewswire)
Oct-25-22 08:30AM	Biopharma Veteran Ivor Macleod Joins SCYNEXIS as Chief Financial Officer (GlobeNewswire) +5.41%
Oct-24-22 08:30AM	SCYNEXIS Presents Positive Interim Data of Oral Ibrexafungerp for Severe Fungal Infections from Ongoing Phase 3 FURI Study During IDWeek 2022 (GlobeNewswire) -7.11%
Oct-20-22 07:00AM	SCYNEXIS Provides Corporate, Commercial and R&D Strategy Updates to Expand Market Potential for Its First-in-Class Antifungal (GlobeNewswire) -14.97%
Oct-11-22 08:30AM	SCYNEXIS to Present Positive Interim Data from the Phase 3 FURI Study of Oral Ibrexafungerp at IDWeek 2022 (GlobeNewswire)
Oct-07-22 09:25AM	Great news for SCYNEXIS, Inc. (NASDAQ:SCYX): Insiders acquired stock in large numbers last year (Simply Wall St.)
Sep-09-22 08:30AM	SCYNEXIS to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Sep-08-22 08:30AM	SCYNEXIS Presents Positive Interim Data of Ibrexafungerp for Refractory Candida Infections from Ongoing Phase 3 FURI Study During the Mycoses Study Group Education and Research Consortium (MSGERC) Biennial Meeting (GlobeNewswire)
Sep-01-22 08:30AM	SCYNEXIS to Present Posters Highlighting Ibrexafungerp Data at Four Upcoming Scientific Meetings in September 2022 (GlobeNewswire)
Aug-15-22 08:15AM	Scynexis (SCYX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	SCYNEXIS Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-09-22 08:30AM	SCYNEXIS to Report Second Quarter 2022 Financial results and Provide a Corporate Update on August 15 (GlobeNewswire) -6.90%
Aug-04-22 08:30AM	SCYNEXIS Presents Positive Data from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections During the 2022 IDSOG Annual Meeting (GlobeNewswire) +8.70%
Aug-01-22 08:30AM	SCYNEXIS Announces U.S. Food and Drug Administration Acceptance and Priority Review of the Supplemental New Drug Application for BREXAFEMME® (ibrexafungerp tablets) for Prevention of Recurrent Vaginal Yeast Infections (GlobeNewswire)
Jul-19-22 08:30AM	SCYNEXIS Presents Positive Data from Phase 3 CANDLE Nested Sub-Study Investigating Ibrexafungerp in Women with Recurrent Yeast Infections Who Failed Fluconazole During the ISSVD XXVI World Congress and International Vulvovaginal Disease Update (GlobeNewswire)
Jul-14-22 08:30AM	SCYNEXIS to Present Data from the CANDLE Nested Sub-Study of Ibrexafungerp During the International Society for the Study of Vulvovaginal Disease (ISSVD) XXVI World Congress and International Vulvovaginal Disease Update (GlobeNewswire)
Jun-29-22 07:06AM	The past five years for SCYNEXIS (NASDAQ:SCYX) investors has not been profitable (Simply Wall St.)
Jun-23-22 08:30AM	SCYNEXIS Announces Initiation of New Phase 3b Study (VANQUISH) to Evaluate Oral Ibrexafungerp as a Treatment for Complicated Vulvovaginal Candidiasis (VVC) in Patients Who Failed to Respond to Treatment with Fluconazole (GlobeNewswire)
Jun-08-22 08:30AM	SCYNEXIS Announces Submission of Supplemental New Drug Application of BREXAFEMME® (ibrexafungerp tablets) to the U.S. Food and Drug Administration for an Expanded Indication for the Prevention of Recurrent Vaginal Yeast Infections (GlobeNewswire)
Jun-03-22 04:05PM	SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-20-22 08:30AM	SCYNEXIS to Present at Upcoming H.C. Wainwright Global Investment Conference (GlobeNewswire)
May-12-22 08:35AM	Scynexis (SCYX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:00AM	SCYNEXIS Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
May-10-22 08:30AM	SCYNEXIS Presents New Interim Positive Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting (GlobeNewswire)
May-05-22 08:30AM	SCYNEXIS to Report First Quarter 2022 Financial Results and Provide a Corporate Update on May 12 (GlobeNewswire) -6.90%
May-04-22 08:30AM	SCYNEXIS to Present New Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting (GlobeNewswire)
Apr-30-22 08:55AM	The CEO, President & Director of SCYNEXIS, Inc. (NASDAQ:SCYX), Marco Taglietti, Just Bought 68% More Shares (Simply Wall St.)
Apr-27-22 08:30AM	SCYNEXIS Presents Data Analyses Showing Ibrexafungerps Potential to Fight Invasive Candidiasis and Candidemia, Including Infections Caused by Candida Auris, During the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases (GlobeNewswire)
Apr-26-22 05:18PM	SCYNEXIS Announces Closing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants (GlobeNewswire)
Apr-22-22 08:15AM	SCYNEXIS Announces Pricing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants (GlobeNewswire) -25.80%
08:00AM	SCYNEXIS Announces Positive Interim Data from Phase 3 FURI and CARES Studies Highlighting Oral Ibrexafungerp's Potency Against Severe Fungal Infections (GlobeNewswire)
Apr-21-22 04:01PM	SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants (GlobeNewswire)
Apr-20-22 08:30AM	SCYNEXIS to Present Positive Interim Data from Ongoing FURI and CARES Studies at the 32nd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Being Held April 23-26 in Lisbon, Portugal (GlobeNewswire)
Apr-19-22 08:30AM	SCYNEXIS Secures Additional Commercial Insurance Formulary Coverage for BREXAFEMME® (ibrexafungerp tablets), Providing Access to an Estimated 93 Million Commercially-Insured Lives (GlobeNewswire)
Apr-09-22 08:03AM	Revenue Downgrade: Here's What Analysts Forecast For SCYNEXIS, Inc. (NASDAQ:SCYX) (Simply Wall St.)
Apr-04-22 09:59AM	SCYNEXIS to Participate in Upcoming April Womens Health Medical Conferences (GlobeNewswire)
Mar-31-22 01:37PM	What Type Of Shareholders Make Up SCYNEXIS, Inc.'s (NASDAQ:SCYX) Share Registry? (Simply Wall St.)
Mar-29-22 08:15AM	Scynexis (SCYX) Reports Q4 Loss, Lags Revenue Estimates (Zacks) -12.98%
07:00AM	SCYNEXIS Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-24-22 08:30AM	SCYNEXIS to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Business Update (GlobeNewswire)
Mar-08-22 08:30AM	SCYNEXIS Named to Fast Companys 2022 Top 50 List of the Worlds Most Innovative Companies (GlobeNewswire)
Mar-04-22 05:00PM	SCYNEXIS Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-02-22 08:30AM	SCYNEXIS to Participate in Upcoming Scientific Conferences and Events (GlobeNewswire)

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.

Open in Screener

TBF

ProShares Short 20+ Year Treasury -1x Shares

Apr 19 • 11:40AM ET

24.61

Dollar change -0.10
Percentage change -0.41	%

Financial • Exchange Traded Fund • USA • NYSE

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

TBF ProShares Short 20+ Year Treasury -1x Shares daily Stock Chart

Held by: DYFI

Category	Bonds - Leveraged / Inverse	Asset Type	Bonds	Tags	U.S.	Return% 1Y	20.16%	Shs Outstand		Perf Week	1.31%
Sponsor	ProShares	ETF Type		Tags	treasuries	Return% 3Y	14.24%	Total Holdings	11	Perf Month	4.31%
Fund Family		Bond Type		Tags	bonds	Return% 5Y	3.71%	AUM	134.64M	Perf Quarter	5.48%
Index	ICE U.S. Treasury 20+ Year Bond Index	Average Maturity		Tags	inverse	Return% 10Y		NAV%		Perf Half Y	-6.65%
Index Weighting		Commodity Type		Tags	-	Return% SI		NAV/sh		Perf Year	13.98%
Active/Passive		Quant Type		Tags	-	Flows% 1M	40.73%	52W Range	20.99 - 27.03	Perf YTD	11.30%
Dividend TTM	1.07 (4.35%)	ESG Type		Tags	-	Flows% 3M	29.87%	52W High	-8.96%	Beta	-0.19
Dividend Ex-Date	Mar 20, 2024	Dividend Type		Sector/Theme		Flows% YTD	20.81%	52W Low	17.26%	ATR (14)	0.27
Expense	0.92%	Structure Type		Region		Flows% 1Y		RSI (14)	63.15	Volatility	0.86% 0.83%
Option/Short	Yes / Yes	Growth/Value		Dev/Emerg		Flows% 3Y		Rel Volume	0.35	Prev Close	24.71
Inverse/Leveraged		Market Cap		Currency		Flows% 5Y		Avg Volume	359.09K	Price	24.61
SMA20	2.89%	SMA50	4.14%	SMA200	3.51%	Trades		Volume	45,873	Change	-0.41%

May-09-22 04:30PM	ETFs For A Rising Rate Environment (ETF.com)
Aug-16-19 04:10PM	Bearish Treasury Bond ETFs for the Contrarian Investor (ETF Trends)
Jun-25-19 09:13AM	The Top 5 Inverse-Bond ETFs (Investopedia)
Oct-09-18 11:24AM	Yields Are Soaring: Here's How to Short Treasury With ETFs (Zacks)
Oct-05-18 02:30PM	Treasury Yields at New 7-Year High: ETF Strategies to Play (Zacks)
03:10PM	Loading…
Aug-23-18 03:10PM	ETF Strategies to Navigate Rising Rate Conditions (ETF Trends)
Aug-22-18 04:36PM	Rising Interest Rates and ETF Strategies to Manage Them (ETF Trends)
May-17-18 04:55PM	5 Fixed-Income ETFs as U.S. Interest Rates Rise (ETF Trends)
May-16-18 11:05AM	10-Year Yields At 7-Year High: Short Treasury With These ETFs (Zacks)
Apr-30-18 04:49PM	Slowing Foreign Demand Trouble for Treasury ETFs (ETF Trends)
Mar-19-18 03:10PM	Treasury ETFs Move Lower Ahead of FOMC Meeting (Investopedia)
Mar-13-18 05:22PM	6 ETF Strategies to Hedge Rate Risk (ETF Trends)
Feb-21-18 12:05PM	7 Ways to Play Rising Yields With Inverse Treasury ETFs (InvestorPlace)
Jan-04-18 01:45PM	Analyzing the Yield Curves Ongoing Flatness (Market Realist)
Nov-29-17 09:05AM	Why Decreasing Credit Spreads Are a Cause for Concern (Market Realist)
08:00AM	Loading…
Nov-02-17 08:00AM	Trending: Catalonia's Push for Independence Continues (ETF Database)
Oct-26-17 05:04PM	Are Declining Yield Spread Worries Done for Now? (Market Realist)
Sep-27-17 09:13AM	How Credit Spreads May React to the Feds September Statement (Market Realist)
Aug-25-17 05:02PM	Why Interest Rate Spreads Are Growing (Market Realist)
Jul-25-17 09:00AM	ProShares Launches First U.S. Equity ETF Specifically Designed to Outperform in a Rising Rate Environment (Business Wire)
Jul-10-17 12:09PM	Bond ETFs Bull Run to End Finally? (Zacks)
Jun-22-17 08:00AM	Trending: China Celebrates as MSCI Endorses Nation's A-Shares (ETF Database)
May-11-17 12:50PM	Follow Gundlach's Insight with These ETFs (Zacks)
Apr-10-17 02:12PM	Ask Arora: Can China hurt the U.S. with the $1 trillion-plus in Treasury bonds it holds? (MarketWatch)
Mar-31-17 12:35PM	FMHR Final Trades: Intel, Treasurys, and more (CNBC Videos)
Mar-16-17 08:00AM	Trending: South Korea in Spotlight as President Park is Ousted (ETF Database)
Mar-15-17 04:15PM	Trump solves central bankers biggest problem (MarketWatch)
12:35PM	How to Hedge Your Portfolio against Interest Rate Risk (Market Realist)
Mar-07-17 09:30AM	The Zacks Analyst Blog Highlights: ProShares Short 20+ Year Treasury ETF, Direxion Daily 20+ Year Treasury Bear 1x Shares, iPath US Treasury Long Bond Bear ETN, UltraPro Short 20+ Year Treasury ETF and Direxion Daily 20+ Year Treasury Bear 3x Shares (Zacks)
Mar-06-17 10:23AM	March Rate Hike in the Cards: Bet on These Inverse Treasury ETFs (Zacks)
02:52AM	Loading…
Nov-22-16 02:52AM	These 3 markets are ripe for a big reversal (MarketWatch)
Nov-14-16 09:56AM	Trump Win Sparks Sell-Off in Bonds: Short with These ETFs (Zacks)
Nov-11-16 08:34AM	Interest rates peaked? Joe says bond holders hope so!
Oct-13-16 04:30PM	ProShares Leveraged and Inverse Treasury ETFs Change Benchmark (Business Wire)
Oct-11-16 10:08AM	Interest rates bouncing off double bottom?
Oct-07-16 04:49PM	Should You Short European Bonds due to Taper Talks? (Market Realist)
Oct-05-16 10:57AM	Bonds create bearish wick (reversal pattern) at resistance
Sep-29-16 01:10PM	What should you do if Trump is right about a bond bubble? (MarketWatch)
Sep-23-16 10:24AM	How Inverse ETFs Can Help You Play Fed Rate Hike Decisions (Benzinga)
Sep-22-16 06:09PM	6 Must-Reads As Emerging Market ETF Hits 52-Week High (Barrons.com)
Sep-15-16 10:00AM	Trending on ETFdb.com: Volatility Makes Its Return to the Financial Markets
Sep-14-16 08:20AM	Doc Copper, breakout here would concern bonds
Sep-13-16 03:57PM	China & India Oil Demand "Wobbling," ETFs Battered (Barrons.com)
Sep-12-16 11:08AM	Profit from Wall Street Sell-Off with These Inverse ETFs
Sep-02-16 09:38AM	Interest rates testing breakout level, says Joe Friday
Aug-12-16 01:48PM	7 Best ETF Picks For Rest Of 2016: Gearing For Inflation As Economy Strengthens
Jul-25-16 08:25AM	ETFs to Hedge Rising Risks in Treasury Bonds
Jul-14-16 08:53AM	Govt Bonds peaking as it kisses potential resistance?
Jul-13-16 11:30AM	Bearish on Upcoming Banking Earnings? Bet on These ETFs
Jun-27-16 12:52PM	Beat Brexit-Induced Sell-Off via These Inverse ETFs
May-30-16 10:58AM	Why the Equity Short Bias Hedge Fund Underperformed in April
May-14-16 12:01AM	[$$] Time to Hedge Stock Bets? (Barrons.com)
Apr-29-16 11:02AM	Elaine Knows Best; Starbucks a Little Lukewarm: Best of Kass (TheStreet)
Apr-08-16 12:07PM	How Has the Equity Short Bias Hedge Fund Strategy Worked in 2016?
Mar-28-16 09:30AM	Zacks Investment Ideas feature highlights: VelocityShares 3x Inverse Crude Oil ETN, ProShares UltraShort Bloomberg Crude Oil, Direxion Daily Energy Bear 3X ETF, ProShares UltraShort Oil & Gas and ProShares Short Oil & Gas
Mar-11-16 02:24PM	The 6 Best Alternative Strategies in a Rising Rate Environment (HYHG, TBF) (Investopedia)
Feb-26-16 11:04AM	DeMark: S&P Set To Fall 8% To 10% In March
09:30AM	The Zacks Analyst Blog Highlights: ProShares Short Financials ETF, ProShares UltraShort Financials ETF, ProShares UltraPro Short Financial Select Sector ETF, ProShares Short S&P Regional Banking ETF and Direxion Daily Regional Banks Bear 3x
Feb-25-16 10:11AM	Six Ways to Short Financial Stocks with ETFs
Feb-17-16 09:10AM	Bonds in trouble after creating this bearish pattern?
Jan-20-16 08:03PM	ETFs Reverse Sharply But S&P 500 Still Near 2014 Low (Investor's Business Daily)
Jan-19-16 10:34AM	These 3 ETFs Will Protect You in a Bear Market (TheStreet)
Jan-04-16 02:55PM	Billionaire Prediction: China Central Bank Easing Will Shape 2016 (Forbes)
Dec-14-15 08:32AM	This Junk Bond ETF Is Packing On The Assets
Nov-20-15 02:53PM	Why Real US Rates Have Been Climbing
Oct-02-15 12:52PM	Emerging Markets In Review: Mexico, China, Petrobras & Currency (Barrons.com)
Sep-25-15 09:00PM	A 'Fundamentalist' Leans Technical; The Case for Muni Bonds: Best of Kass (TheStreet)
Aug-14-15 01:01PM	China's Emerging Market Impact. In Sum: Dim? (Barrons.com)
Aug-13-15 08:22AM	Should You Be Shorting the Dow and S&P 500? (TheStreet)
Aug-06-15 08:20AM	Right Here, Right Now for This Bearish Treasury ETF
Jul-28-15 04:20PM	Falling Inflation Expectations Support Treasury Bond ETF Rally
10:00AM	Enter the Bear: How to Win With ETFs as Chinese Stocks Tumble (TheStreet)
Jul-08-15 01:37PM	Inverse, Leveraged ETF Assets Reach a Record $63 Billion
Jun-29-15 12:26PM	Is a Bond Market Selloff Coming? (Investopedia)
Jun-24-15 09:00AM	A Bond Rotation Could Support Stock ETFs
Jun-19-15 12:57PM	June Swoon for Bond ETFs
Jun-15-15 09:02AM	Bond reversal pattern suggest challenges for stocks ahead?
Jun-12-15 10:53AM	The 'Bigger Short' Or How To Play This Crazy Bond Market (Forbes)
Jun-05-15 08:59AM	Bonds could be in big trouble if this gives way
Jun-03-15 09:16AM	Bond players-beware of what happens here
Jun-01-15 08:20AM	Inverse Bond ETFs to Hedge Growing Risk in Fixed-Income Market
May-21-15 12:30PM	TLT Woes Stoke Interest in Leveraged Bond ETFs
12:15AM	How To Short The U.S. Bond Market (Investopedia)
May-08-15 04:50PM	Is the market decline real ... or is it Memorex?
May-06-15 08:38AM	Could the Fed be losing control over interest rates?
May-04-15 02:28PM	Buffett Says He'd Short Long-Term Treasuries if He Could (Barrons.com)
11:25AM	Bearish Bond ETFs Back in Style
May-01-15 04:27PM	Bond bear ETFs post best week in two months (Reuters)
Apr-02-15 07:15PM	Are Fund Pros Who Eat Their Cooking Superior? (Barrons.com)
Apr-01-15 06:01AM	Why Im Shorting Bonds
Mar-25-15 04:20PM	Seventh and pre-election year seasonal chart of 30-year bond
Mar-12-15 11:55AM	Short Rate-Sensitive Securities with These ETFs - ETF News And Commentary
Feb-19-15 08:41PM	Investors are still not impressed with the long bond
Feb-11-15 05:27PM	More downside likely for 30-year Treasury bond
10:44AM	Interest rates rise 19% of late, a shift taking place?
Feb-05-15 12:03PM	Big Top in bonds could be good for commodities and stocks!
Feb-04-15 09:26AM	10-Year yield rose almost 9% of late, new trend at hand?

ProShares Short 20+ Year Treasury seeks daily investment results, before fees and expenses, that correspond to the inverse (-1x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index includes publicly-issued U.S. Treasury securities with minimum term to maturity greater than or equal to twenty years and have $300 million or more of outstanding face value, excluding amounts held by the Federal Reserve. The fund is non-diversified.

open in screener | open in yahoo | open in marketwatch | open in google

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

SCYX

Scynexis Inc

TBF

ProShares Short 20+ Year Treasury -1x Shares

Upgrade your FINVIZ experience